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Abstract 
Combination cancer chemotherapy provides an important treatment tool, both as an 
adjuvant and neoadjuvant treatment, this shift in focus from mono to combination 
therapies has led to increased interest in drug delivery systems (DDS).  DDSs, such 
as polymersomes, are capable of encapsulating large amounts of multiple drugs with 
both hydrophilic and hydrophobic properties simultaneously, as well as offering a 
mechanism to combat multi drug resistant cancers and poor patient tolerance of the 
cytotoxic compounds utilised. In this article, we report the formulation and evaluation 
of a novel electroneutral polymersome capable of high encapsulation efficacies for 
multiple drugs (Doxorubicin, 5-Fluorouracil and leucovorin). The in-vivo biodistribution 
of the polymersome were established and they were found to accumulate largely in 
tumour tissue. Polymersome encapsulating the three chemotherapeutic drugs were 
assessed both in-vitro (BxPC-3 cell line) and in-vivo (following intratumoral and 
intravenous administration) and compared with the same concentration of the three 
drugs in solution. We report better efficacy and higher maximum tolerated dose for our 
combination drug loaded polymersomes in all experiments. Furthermore, 
intratumorally injected combination drug loaded polymersomes exhibited a 62% 
reduction in tumour volume after 13 days when compared with the free combination 
solutions. A smaller differential of 13% was observed for when treatment was 
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administered intravenously however, importantly less cardiotoxicity was displayed 
from the polymersomal DDS. In this study, expression of a number of survival-relevant 
genes in tumours treated with the free chemotherapy combination was compared with 
expression of those genes in tumours treated with the polymersomes harbouring those 
drugs and the significance of findings is discussed. 
 
Key words 
Combination chemotherapy, polymersome, pancreatic cancer, nanoparticle, drug 
delivery system 
1.0 Introduction 
The advantages offered by combining two or more chemotherapies has been 
recognised and documented from as early as the mid twentieth century [1]. It is now 
widely accepted that most cancers respond better to combination drug therapy rather 
than single agent therapy. The accessibility of combination therapies has benefitted 
from the development of novel formulations such as nanoparticle (NP) drug delivery 
systems (DDSs). The first commercially available DDS was that of Doxil® in 1996, a 
liposome containing the chemotherapeutic agent doxorubicin (Dox) [2,3]. Liposomes 
have been investigated for the delivery of many anticancer agents such as 
anthracyclines[4-6], platinum compounds[7], antimetabolites[8] and vinca alkaloids[9-
11] aiming to reduce their side effects without affecting their efficacy. Liposomes take 
advantage of the enhanced permeability and retention (EPR) effect of the tumour 
vasculature [12,13]. Co-encapsulation of multiple drugs in liposomes has shown to 
provide a synergistic action increasing their efficacy [14-16]. Although there is much 
evidence to suggest that liposomes have had a significant impact on existing 
chemotherapeutic treatments, their drawbacks include low stability and shelf life and 
diffusion of the drug across the liposomal membrane with time [17]. The limitations of 
liposomal delivery systems have led to a shift in focus towards more stable 
alternatives. Discher et al. [18] demonstrated in the late 1990s, the ability of diblock 
copolymers to assemble into bilayer vesicles termed polymersomes [18,19]. 
Polymersomes provide an alternative DDS by combining the advantages of bilayer 
forming liposomes with enhanced stability and shelf life [20,21]. The polymer 
backbone can be designed to include desirable properties such as biodegradability 
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and biocompatibility [22,23]. The large molecular weights of polymers used for these 
structures can significantly improve their membrane properties such as permeability, 
thickness and robustness [24]. Similar to liposomes, polymersomes have the ability to 
encapsulate both hydrophilic and hydrophobic compounds, however owing to the 
larger size of the hydrophilic cores [25] and thicker hydrophobic bilayer [26], the 
amount of encapsulated drug is increased. Recently there have been some interesting 
examples of polymersomes encapsulating multiple anticancer drugs [27-29]. Dox and 
paclitaxel loaded polymersomes have shown  enhanced anticancer activity against 
head and neck squamous cancer cells [30] whereas siRNA co-encapsulated with Dox 
in block copolymer polymersomes in human gastric cancer cell lines has shown 
increased efficacy at lower doses [31]. There are further examples of combination 
anticancer therapy using 5-Fluorouracil (5-FU) and Dox loaded in NPs such as 
dendritic nanomicelles [32], polymer drug conjugated NPs [33] and nanocomplexes 
[34] all displaying a synergistic action against different types of cancer [35]. Thus, NP 
DDSs are proving to be a valuable tool for the co-delivery of multi drugs, they are not 
only effective in treating resistant and recurrent tumours but also have the potential to 
reduce the time restraints of current combination therapies which are often delivered 
over a number of consecutive days.  
In this manuscript, we describe the simultaneous encapsulation of three anticancer 
agents, Dox, 5-FU and leucovorin (LV), into a random copolymer polymersome.  We 
report excellent encapsulation efficiencies with both single and multiple occupancy 
within the polymersomes with the hydrodynamic radius suitable for endocytosis. The 
in-vitro analysis suggests that the polymersome formulation significantly enhances the 
efficacy observed with the free drug combination therapy. We describe, for the first 
time, the biodistribution of this particular DDS in-vivo using fluorescence imaging to 
show enhanced tumour accumulation. The therapeutic efficacy of the loaded 
polymersomes was examined using  ectopic pancreatic BxPC-3 tumours in mice after 
both intratumoral and intravenous injection where we report a reduction in tumour 
growth when compared with treatments using the free solutions. Finally, the treated 
tumours were analysed for the  expression of forty relevant genes. Treatment with the 
combination drug loaded polymersomes caused a greater reduction in pro- survival 
gene expression in lesions when compared  with expression of those genes following 
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treatment with the free drug to combination and the implications of these findings are 
discussed 
 
2.0 Materials and Methods 
Materials 
DOX-HCl, 5-FU, LV calcium, indocyanine green (ICG), dialysis membrane (MWCO 
12-14kDa), PBS tablets pH 7.2 and chloroform were obtained from Sigma-Aldrich, UK. 
RPMI 1640, FBS, pen/strep were sourced from Thermofisher Scientific, UK. Matrigel® 
basement matrix was acquired from Corning Inc. 
2.1 Preparation and characterisation of polymersomes 
Polymersomes were prepared from a previously described random co-polymer [36] 
containing polyethylene glycol (PEG, Mn 500Da), cholesteryl and a decyl chain in a 
73:12:15 %w/w ratio. Synthesis of the polymer is well documented with 
characterisation carried out using GPC (Agilent MDS-THF, data collected by Agilent 
GPC/SEC Software Version 1.2.3182.29519). Formulation was achieved using the 
reverse phase evaporation method; 0.5mL polymer in chloroform (5mg mL-1) was 
evaporated to dryness under reduced pressure in a round bottom flask to form a thin 
film. Depending on the application an appropriate volume and concentrations of Dox, 
5-FU and LV were added on top of the film and again evaporated to dryness under 
the same conditions. 1mL Chloroform was added to the round bottom flask and 
sonicated for 15 minutes using a Branson 3510 bath sonicator (230V) at room 
temperature, after which 0.5mL of the polymer in PBS (5mg mL-1) and 0.5mL PBS 
were added and the resulting mixture sonicated for a further 30 minutes forming an 
emulsion. The chloroform layer was then under reduced pressure at 45℃. The 
resulting suspension was freeze dried and resuspended as per requirement. Particle 
size and zeta potential  of polymersomes were determined  using Malvern Nano-ZS 
Zetasizer without the use of any size extrusion techniques. SEM images were carried 
out by applying a small amount of the polymersome onto an aluminium stub. The 
sample was then lyophilised overnight before being sputter coated with gold and 
palladium. The images were recorded using a FEI Quanta SEM under a high vacuum 
in secondary electron mode.  
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2.2. Encapsulation efficiency and release studies of combination drugs 
Encapsulation efficiency of the polymersomes were evaluated by centrifugal filtration 
using a dialysis membrane and centrifuging the polymersomes at 4°C at 3000rcf for 2 
hours. The polymersomes were prepared as described in section 2.1, following the 
creation of a thin polymer film, 100 µL Dox (0.116 mg mL-1 PBS), 100 µL 5-FU (5.2 
mgs mL-1 PBS) and 100 µL LV (25.6 mgs mL-1 PBS) was added and the solution 
evaporated to dryness with the chloroform added as above for the combination 
solutions within the polymersome. The freeze dried sample was reconstituted in 1 mL 
PBS (containing 5 mg mL-1 polymer, 11.6 µg mL-1 Dox, 0.52 mg mL-1 5-FU and 2.56 
mg mL-1 LV), the individual polymersomal formulations were prepared to contain an 
identical amount of one component (only one from: 11.6 µg mL-1 Dox, 0.52 mg mL-1 5-
FU or 2.56 mg mL-1 LV) alongside 5 mg mL-1 polymer. 0.5 mL of each of the 
polymersome suspensions were added to a semipermeable membrane (MWCO 12-
14kDa), secured at both ends and suspended within a centrifuge tube before 
centrifugation. The resultant filtrate was collected and analysed for unencapsulated 
drug. Dox was analysed by fluorescence spectroscopy at Ex 485nm/Em 580nm (y = 
91.324x, R²= 0.9881), 5-FU and LV by UV spectroscopy at absorbance maximum 
265nm(y =0.0581x, R² = 0.9992) and 285nm (y = 0.0543x, R² = 0.9998) respectively. 
In vitro release studies of polymersomes were conducted after removing the 
unencapsulated drug/s and keeping the polymersomes in the sealed dialysis 
membrane. The sealed semi permeable membrane was stirred in 10 mL PBS 
maintained at 37°C, samples were removed at fixed intervals of time and analysed for 
individual drug concentration, the same volume of PBS was replaced after each 
removal to maintain sink conditions. 
2.3. In-vitro study to establish efficacy 
BxPC-3 cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 
1% pen/strep. 100 µl, 1x105 cells mL-1 were seeded into each well on 96 well plates 
and allowed to adhere overnight. Polymersome solutions were prepared as described 
for the encapsulation efficiency and release studies, and sterile filtered with a 0.45µm 
Millex MCE syringe filter. 100µl of either free solution of individual drugs at identical 
concentrations, combination free solutions or combination drugs encapsulated in 
polymersomes were applied to  cells generating a 1:1 dilution of test solution with the 
  
6 
 
cell media, giving final cell concentrations of; 5.8 µg mL-1 Dox, 0.26 mg mL-1 5-FU or 
1.28 mg mL-1 LV and 2.5mg mL-1 polymer. The cells were then  incubated at 37℃ 
(20% O2 5% CO2 ) for 22 hrs.  An MTT assay was then performed by incubating each 
well with 20µl of MTT solution (5mg/ml in PBS) and 100 µl of fresh medium for 3 hours 
and reading the absorbance in DMSO at 570nm using a Fluostar Omega microplate 
reader. 
2.4. In-vivo biodistribution assay of polymersomes 
In these studies, all animals were treated humanely and in accordance with licenced 
procedures under the UK Animals (Scientific Procedures) Act, 1986.  Animals were 
anaesthetised using 150µl intraperitoneal injection of water for injection: hypnorm: 
hypnovel (2:1:1) (VetaPharma Ltd., U.K.).  50µl polymersomes (5mg mL-1) loaded with 
0.2mg mL-1 ICG were prepared as previously described with 100 µL of 2mg mL-1 ICG 
replacing the Dox/5-FU/LV and sterile filtered with a 0.45µm Millex MCE syringe filter 
before being injected into the tail vein of mice previously implanted with ectopic BxPC-
3 tumours as described in section 2.5. Following administration, animals were placed 
in Xenogen IVIS® Lumina imaging system chamber maintained at 37°C equipped  with 
an ICG filter set (Ex 705–780 nm; Em 810–885 nm). Images were recorded at regular 
intervals up to 22 hours to observe the in-vivo biodistribution of the DDS in real time. 
After 22 hours, the mice were sacrificed and their organs and tumours were harvested 
and imaged for the presence of ICG fluorescence. All data were analysed using Living 
Image® software version 2.60 and reported relative to the background emission.  
2.5. Treatment efficacy after Intratumoral and intraveneous injection 
BxPC-3 cells (5x106 cells per mouse) were resuspended in RPMI 1640 medium and 
Matrigel® in 1:1 ratio and implanted subcutaneously into the rear dorsum of NOD-
SCID mice (NOD.CB17-Prkdcscid/NCrHsd). Tumour formation occurred 
approximately 2 weeks after tumour cell implantation, tumours were measured via 
calipers and tumour volume calculated using the formula (LxWxH)/2).  Once tumours 
reached 200-250mm3 animals were grouped and treatment commenced. 
After the ectopic tumours reached the desired volume, the mice were randomly 
segregated into 6 groups of 3 or 4 mice in each group. Prior to treatment animals 
receiving the intratumoral injections were anaesthetised using intraperitoneal 
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administration of Hypnorm/Hypnovel.  Treatment groups consisting of; control 
untreated animals; those treated with empty polymersomes (intratumoral), 
combination solution (intratumoral), combination loaded polymersomes (intratumoral), 
combination solution (I36V) and combination loaded polymersomes (IV). The 
concentration of 5-FU and LV to be added was calculated using the therapeutic range 
in humans (450-600 mg/m2 and 20 – 100 mg/m2 respectively)(Table S1). Due to the 
extremely recalcitrant nature of pancreatic cancer the concentration for Dox was 
higher than the therapeutic range (generally 40 – 75 mg/m2) but in line with similar 
studies [37]. Calculations were based on an average surface area of an adult human 
body being 1.73m2 with an average weight of 60 kg. Calculations were originally based 
on an estimated average mouse weight of 20g and adjusted to allow for the actual 
average weight of the mice used of 23.5g. Solutions of 100µl Dox (5mg mL-1 in water), 
250µl 5-FU (8mg mL-1 in water) and 50µl LV (5mg mL-1 in water) were added to the 
polymer thin film and evaporated as before. The final freeze dried sample was 
resuspended in 50 µL PBS to generate the required concentrations and sterile filtered 
with a 0.45µm Millex MCE syringe filter. Polymersomes (polymer (42.5mg/kg) loaded 
with Dox (4.3mg/kg), 5-FU (17mg/kg) and LV (2.1mg/kg)) were injected either 
intratumorally or intravenously at 100µl volume on Day 0 and Day 5 of treatment in 
mice according to their respective groups whereas the untreated group received no 
treatment. Tumour volume and body weight was measured every day for 13 days after 
intratumoral injection and 7 days after intravenous injection. On completion of data 
collection, mice were sacrificed and their tumours and hearts were harvested. Hearts 
were weighted and stored in formalin free tissue fixative for further observations. 
Tumour doubling time was calculated using an online calculator [38].  
2.6 Assessment of Cardiotoxicity after intravenous treatment 
Hearts from the above experiment were weighted and histologically stained in order 
to assess cardiotoxicity.  Fixed hearts were dehydrated in a series of ascending 
concentrations of methanol; 50%, 70%, 90% and 100% (one hour each).Tissue 
samples were washed twice in 100% methanol (one hour each). Samples were  
cleared with a xylene substitute (Sigma, UK) for 4 hours and embedded in molten 
paraffin wax (Sigma, UK).  A microtome (RM2135; Leica, Germany) was used to 
section heart tissue to 5µm thickness.  Sections were placed on glass slides and dried 
overnight before being hematoxylin-eosin stained (H & E). 
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2.7 Gene expression analysis on xenografts treated with combination 
polymersomes  
To establish the effect of drug loaded polymersomes on the expression of specific 
genes involved in the development and progression of pancreatic cancer. 40 
candidate genes involved in pancreatic cancer progression were analysed with 28 of 
these having a Cp value of less than 40 (BID, BAX, BCL2, BCL2L1, BAD, BIK, 
EPCAM, MET, ALDH1A1, VEGFA, VEGFC, NME1, CA9, CTGF, RUNX2, CNDP2, 
TFE3, ARL8B, CLN3, TOP2A, HIF1A, ABCC1, AGA, CLCN7, CASP3, IL8, NANOG 
and SOX2). Tumours in mice from untreated, combination solution (IV) and 
combination polymersomes (IV) were excised at the experimental endpoint (Day 7).  
Tumours were snap-frozen using liquid nitrogen and RNA was extracted using Trizol 
reagent (Life Technologies) in accordance with the manufacturer’s instructions [39]. 
1.25 µg of RNA per tumour was reverse transcribed using the First Strand cDNA 
synthesis kit (Roche) in accordance with the manufacturer’s instructions [40] and the 
cDNA from the tumours in each group were pooled. Samples were analysed in 
duplicate on Roche RealTime Ready custom 96 well gene panels (Roche) containing 
the relevant target genes.  The results were normalised to a reference gene set (Beta 
actin, 18s ribosomal RNA and GAPDH) and the fold changes in gene expression in 
tumours treated with combination solutions and with combination polymersomes were 
compared to untreated expression levels; genes considered up-regulated (≥2) or 
down-regulated (≤0.5) and those which satisfied a p value <0.05 (to the left of the 
vertical green line, Figure 13A) were deemed statistically significant (student t-test). 
Results shown are mean ± SE of ≥3 pooled tumours analysed in duplicate.  
2.8 Statistical analysis 
All data are reported as n=3 unless otherwise stated. Error bars indicate ±SEM. 
Statistical significance of groups was determined using Unpaired Student’s t test in 
Graphpad Prism Version 5.01.  
3.0 Results and Discussion 
3.1 Characterisation and evaluation of polymersomes 
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The amphiphilic random copolymer used for the preparation of polymersomes was 
composed of three components, two hydrophobic components comprising of a decyl 
chain, and cholesterol as well as a hydrophilic component, poly (ethylene) glycol 
(PEG) with an average molecular weight of 500Da. Polymerisation was achieved by 
free radical polymerisation using AICN as the initiator. The mass of the polymer was 
determined by GPC and found to have a Mn of 3.2KDa with a PDI of 3.6.  As the 
polymer formed was a random co-polymer, the exact positioning of each monomer 
relative to each other is not guaranteed. However, on formation of the polymersome, 
due to the amphiphilic nature of the components the PEG 500 forms the hydrophilic 
inner core and outer corona of the polymersome whereas the cholesterol and decyl 
chain form the hydrophobic bilayer of the polymersomes as depicted in Figure 1A. 
Multiple drug loaded polymersomes were prepared by the reverse phase evaporation 
method as described above in section 2.1 with each of the three drugs encapsulated 
into the aqueous core. The hydrodynamic radius, PDI, zeta potential and 
encapsulation efficiencies of the polymersome formulations can see seen in Table 1. 
Figure 1B displays the SEM images of the Dox loaded polymersomes, the spherical 
morphology is apparent with the NP’s of a similar size range. The size of all 
polymersomes was found to be less than 300 nm with a PDI of less than 0.5 and low 
zeta potential, all of which are expected for electroneutral NPs of this type. The 
simultaneous encapsulation of 5-FU, Dox and LV eliminates their solution 
incompatibilities and allows their simultaneous administration with enhanced 
therapeutic effect. The encapsulation efficiency of all the compounds was greater than 
70 % (Table 1) and in agreement with similar studies reported in the literature [41,42].  
 
In-vitro release studies indicate that polymersomes demonstrate a burst effect 
followed by a fast release of drugs (Figure 2) with more than 65% of 5-FU released 
within 8 hours, whereas just over 40% for Dox and 30% LV was released after 8 hours 
following the initiation of the study. Almost all of 5-FU was released after 24 hours 
however, release of Dox and LV remained constant. Hence, even though the release 
of Dox and LV was fast initially, it remained steady to roughly less than 50% over 24 
hours. It was concluded that the amphiphilic copolymer polymersomes were 
electroneutral, of appropriate size within the nano range required for endocytosis, with 
PDI’s less than 0.5 indicative of sufficiently monodispersed systems, display good 
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encapsulation of multiple drugs and are capable of releasing their encapsulated cargo 
into the surrounding environment. 
 
3.2. Cell viability studies  
To evaluate the synergistic action of the combination drugs on the cell viability of 
BxPC-3 cells, free solutions of 5-FU, LV and Dox were compared to their combination 
free solution and combination drugs loaded in polymersomes at concentrations 5-FU 
(0.26 mg mL-1) , LV (1.28 mg mL-1 ) and Dox (5.8 µg mL-1 ) and 2.5mg mL-1 polymer. 
As seen in Figure 3, the viability of individual drug solution treated cells were 
91.7±11.0% for Dox, 91.3±8.6% for 5-FU and 107.7±7.0% for LV indicating only limited 
toxicity at the above mentioned concentrations. When the same cells were subjected 
to the combination solution toxicity was higher with 74.9±6.6% viable cells, showing a 
synergistic action with approx. 25% cytotoxicity. The toxicity was greatly enhanced 
when the same concentrations were combined within polymersomes, they displayed 
~65% cell toxicity with only 36.5±3.6% viable cells. Furthermore, polymersomes with 
single/dual occupancy drugs were prepared with identical concentrations and the cell 
viability established. In each of the polymersomes assessed an enhanced toxicity was 
observed when compared to non polymersomal solutions (Fig. S1). The highest 
toxicity was recorded from the 5-FU/LV combination of 49.5% which was marginally 
more toxic than the 5-FU single occupancy polymersome (53% cell viability).  This 
increased toxicity provided by the polymersome encapsulated drugs could suggest 
enhanced uptake of the drugs.   Since the toxicity of the combined drugs in the 
polymersomes was greater than that exhibited by the individual components of the 
formulation, the data suggested that a synergistic effect may be occurring. This could 
provide significant and unforeseen benefits in using such an approach in cancer 
therapy. To compliment this research, a further polymersome was prepared to contain 
a higher (x2) concentration of Dox with all other parameters remaining unchanged. 
The cell viability study (Fig. S2) shows a less than 20% cell viability with the 
combination PS Dox x2, compared with a 48% cell viability achieved from the same 
concentration of free solutions. This data would suggest that a. the loading potential 
of the PS system has not yet been met and b. the synergistic effect could be optimised 
further, thus creating a more potent drug cocktail. However, this higher concentration 
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of Dox was not used in the in-vivo study as cardiotoxicity was of utmost concern, in 
particular with the free solution controls.  
 
3.3 In-vivo biodistribution of polymersomes  
In order to ascertain the behaviour of these polymersomes in-vivo we employed 
polymersomes loaded with Indocyanine green (ICG). ICG is a near infrared dye, 
commonly used for in-vivo imaging because of its water solubility, easy loading into 
NPs, good tissue penetration and reduced light scattering [43,44]. Although the 
method is semi quantitative, it provides the advantage of being able to monitor the 
behaviour of the polymersomes in the body in real time.   Polymersomes loaded with 
ICG (0.2mg/mL) were injected into the tail vein of mice bearing ectopic BxPC-3 
tumour. As seen from 4A, the fluorescence after initial injection shows that 
polymersomes containing the fluorophore were present in the tumour . The 
polymersomes in peripheral circulation (as indicated by the signal from the extremities 
as a surrogate fluorescent signal for circulatory vehicle) slowly started to dissipate with 
a significant amount retained in the tumour tissue as observed 22 hours following 
administration. Whilst the initial signal from the tumour may be attributed to both 
circulating and retained vehicle, a plot of tumour fluorescence expressed relative to 
peripheral tissue fluorescence (Figure 4B) suggests a 6-fold degree of accumulation 
of polymersomes in the tumour after 8 hours as compared to systemic circulation. 
Although the signal disappeared from the peripheral tissues with time, the relative 
amount in the tumour only decreased slightly after 22 hours post injection. To further 
confirm the accumulation of polymersomes in tumour tissue and determine their tissue 
distribution, the mouse was dissected, and individual organs were collected for 
fluorescence observation. Figure 5 shows the individual excised organs with the 
fluorescence emission from each organ quantified and compared to a blank. The 
results suggested that there was a significant degree of polymersome accumulation in 
the tumour, however a significant amount was also seen in the liver. These data 
support our suggestion that the fluorescent signal from circulating vehicle was 
decreasing more rapidly than that in the tumour since the fluorescent signal from more 
highly perfused organs such as the lung and kidney were lower than the less perfused 
tumour tissues.    Figure 5 (insert) displays the fluorescence emission observed from 
the faeces of the mouse before and after injection with polymersome containing ICG, 
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further confirming excretion through the liver. This suggested biodistribution agrees 
with previous studies carried out by Photos et al. and Fei Lu et al [45,46]. They 
demonstrated that PEG based polymersomes were mainly eliminated by the liver 
followed by the spleen with a small amount being eliminated by the kidneys. In 
addition, the lack of accumulation in the heart was an encouraging indication for the 
potential use of NPs with cardio toxic compounds such as Dox.  
 
3.4 In-vivo therapeutic efficacy following Intratumoral injection 
Intratumoral injection has been shown to improve tumour concentrations and tumour-
organ ratios of injected drugs [47]. Our rationale for using it here was to preclude any 
unforeseen pharmacokinetic complications and primarily examine the potential 
therapeutic efficacy of our preparation.   NOD-SCID mice were implanted with BxPC-
3 tumours and the relevant formulation was administered intratumorally when the 
tumour size was appropriate. On Day 0 and Day 5 mice were injected with either the 
combination drug loaded polymersomes (comb PS) or combination of three drugs in 
free solution (comb soln) and their impact on tumour growth was compared with that 
in mice injected with blank polymersomes and those that received no treatment. 
Tumour volume was measured each day until the end of treatment (Day 13).  
Throughout the duration of the study, the body weight of the mice was regularly 
recorded and found to remain steady at 90 ± 10% (Figure 6A) indicative of limited 
toxicity caused by the Intratumoral administration of the chemotherapeutic drugs. The 
individual growth pattern of the tumours is illustrated in Figure 6B for each group. It 
was interesting to note that there was a spiked increase in recorded tumour volume 2 
days after intratumoral injections for both groups containing the therapeutic agents.  
The injections were carried out on Days 0 and 5, the increase is then seen in Days 1 
and 2 and consecutively on Days 6 and 7 for the combination solutions and the 
combination drug loaded polymersome groups. The increase in recorded volume for 
the combination solution treated group is more prominent (30-40%) than those treated 
with the combination drug loaded polymersomes (5-10%). This increase in recorded 
volume is most likely due to the vesicant nature of the Dox [48] and or the inflammatory 
nature of 5-FU [49], causing local inflammation of the surrounding tissues at the site 
of injection. This is further confirmed by the lack of any such increase observed with 
the free polymersome suspension of identical volume. The reason for the reduced 
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immune response observed in the combination drug loaded polymersome may be 
attributed to the protection offered by the polymersome bilayer inhibiting Dox and, to 
some extent 5-FU, from causing such an inflammatory immune response. In addition, 
the particulate nature of NPs allows them to diffuse through the interstitial space and 
lymphatic vessels of the tumour leading to a more homogeneous distribution 
throughout the tumour tissue, causing a less pronounced inflammatory effect.  
Figure 7 displays a photograph of each group containing both the mouse and the 
excised tumour. It is evident that the smallest tumour was excised following 
polymersomal treatment with the combination drugs (comb PS), the next most 
effective treatment was from the free solutions (comb soln) with both the control and 
the blank polymersomes displaying the largest tumours after 13 days. Figure 8A 
shows the percentage increase in tumour weight of all the groups at the end of the 
study. The group treated with blank polymersomes had no effect on the tumour toxicity 
showing 160.2±21.6% increase in tumour weight from the initial and having the same 
trend as the untreated group whose tumour weight increased by 173.5±42.0% after 
13 days. It was anticipated that the free drug solutions would provide good reduction 
in tumour weight since the concentrations of Dox, 5-FU and LV were at therapeutic 
doses. Indeed, the group treated with the combination solution of free drugs exhibited 
a significant reduction in tumour growth with an increase of only 59.6±32.8% tumour 
weight from the start of the experiment. However, the group treated with combination 
drug loaded polymersomes had the maximum cytotoxic effect on the tumour showing 
a decrease of 2.3±20.4% in the tumour weight after 13 days which is significantly better 
than the same concentration of free drug solution.  
Tumour doubling times were calculated to be 10.3±1.20 and 10.0±1.4 days for the 
control group and the blank PS, respectively. In contrast, the rate of tumour growth for 
the combination solutions was calculated to be 18.0±5.0 days whereas the 
combination drug loaded polymersome therapy displayed a tumour doubling time 
calculated to be almost four times slower than the combination solutions at 67.0±22.0 
days (Figure 8B). 
3.5 In-vivo toxicity after Intravenous injection 
The observation of enhanced retention of polymersomes in tumour tissue of ICG 
loaded polymersomes, provided the basis for the exploration of antitumor activity of 
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multiple drugs-loaded polymersomes administered by intravenous injection. Again, 
mice with ectopic BxPC-3 tumours were divided randomly into groups receiving 
intravenous injection of combination free drugs solution (comb soln) on Day 0 and Day 
5, a group receiving combination drug loaded polymersomes (comb PS) at the same 
concentration on Day 0 and Day 5 and finally a control group that received no 
treatment. As with the previous study, the body weights of all mice were recorded on 
a regular basis and data are shown in Figure 9A. The mice treated with combination 
free drug solution (comb soln) displayed a decrease in the body weight from the first 
day of treatment which potentiated after the second treatment and the weight of mice 
fell to 80.0 ± 4.01% from their initial weight indicating accumulated systemic toxicity 
and leading to the termination of the study on day 7. The mice were weary, distressed 
and unable to eat and this further exacerbated weight loss. The mice in the untreated 
and combination drug loaded polymersomes group (comb PS) were relatively healthy 
with only a 10% loss in body weight of the latter towards the end of the experiment. 
The rapid weight loss of mice treated with combination free drug solution is indicative 
of acute cardiotoxicity of Dox at the concentration administered in mice. Dox has been 
reported to exhibit acute cardiomyopathy which is dose dependant leading to 
congestive heart failure at higher doses [50-52]. Other effects of anticancer drugs such 
as 5-FU and Dox include nausea, vomiting, poor appetite, alopecia and hematopoietic 
suppression [53,54]. Although cardiotoxicity of Dox remains the most feared side effect 
of chemotherapy, the encapsulation of Dox into liposomes and other NPs has helped 
reduce its cardiotoxicity, the most common example being the marketed pegylated 
liposomal Dox, Doxil® [55-57]. The encapsulation of the combination drugs into 
polymersomes at the same concentration produced limited toxic side effects in the 
mice indicating a higher maximum tolerated dose. Figure 9B displays the % tumour 
growth of each group.  A steady increase in tumour volume was observed for all three 
groups throughout the 7 days of treatment, with the tumour volume increasing to 
74.8% ± 11.8% in the control group and an increase of 53.7 ± 11.2% in the group 
treated with the combination free drug. Mice treated with combination drug loaded 
polymersomes displayed the lowest increase in tumour volume of 40.1% ± 10.8% from 
initial volume. Following the premature end of the experiment, all the mice were 
euthanized, and their tumours and hearts were excised. Figure 10 displays a 
photograph of one mouse from each group with the corresponding excised tumour. 
This image reinforces the data from Figure 9B and displays the smallest tumour 
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excised being that from the combination drug loaded polymersomal treatment group.  
Although the degree of tumour inhibition afforded in these experiments was not as 
dramatic as that observed when the combination drug-loaded polymersomes were 
administered intratumorally, we believe that these data demonstrate significant 
therapeutic benefit over that observed with the free drug, particularly in terms of 
reducing adverse effects.   It should further be noted that although preliminary in 
nature, the data trend, in terms of tumour size reduction following intravenous 
administration certainly indicates therapeutic advantage and we believe that this could 
be further enhanced by manipulating the dosing regimen.  
To further confirm an effect on tumour size reduction using the intravenous route of 
administration with the polymersome formulation, Figure 11A displays the % increase 
in tumour weight at the end of 7 days. It was found that the tumour weight of mice in 
the untreated group increased to 92.3 ± 17.8% of the initial weight, whereas those in 
the combination free drug solution and the combination drug loaded polymersomes 
treated groups increased by 53.8 ± 13.0% and 40.1 ± 12.5% respectively. 
Furthermore, the calculation of tumour doubling time indicates that it would take 10.3 
± 1.2 days and 14.7 ± 3.7 days for the untreated group and combination free drug 
solution group tumours to double in size.  However following treatment with the 
combination drug loaded polymersome formulation, tumours would take the longer 
time of 21.3 ± 7.9 days to double in size (Figure 11B) again confirming a negative 
impact on tumour growth by the polymersome formulation. 
Further evaluation of systemic cardiotoxicity was carried out by the observation of the 
reduction in heart weights after the completion of the study (Figure 12). It was found 
that mice treated with combination free drug solution showed an average heart weight 
of 88 ± 2 mg which was lower than those of either the untreated group or the 
combination drug loaded polymersome treated groups which had heart weights of 120 
± 2 mg and 100 ± 1 mg respectively.  Furthermore, H & E staining of hearts revealed 
an increase in nuclei in tissue from animals treated with the Combo Soln. compared 
with heart tissue from either those treated with the Combo PS or untreated animals 
(Figure 12 B).  This suggested that cellular recruitment may be occurring to address 
toxic insult caused by the drugs in free solution.  This was confirmed by the presence 
of extensive necrotic regions and evidence of cellular mobilisation in tissue harvested 
from animals treated with the Combo Soln. (Figure 12C) and a distinct absence of both 
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in animals treated with the Combo PS or untreated animal. This again demonstrates 
the potential benefit offered by the novel polymersome formulation and clearly 
demonstrates a cardio-protective effect afforded by the approach, presumably 
because of modifying the bioavailability of the cardiotoxic anthracycline (Dox) in the 
formulation.  
 
3.6 The effect of treatment with combination polymersomes on expression of 
candidate gene in tumours. 
RealTime ready custom plates were used to compare the expression of 40 candidate 
genes involved in pancreatic cancer progression. BxPC-3 tumours were harvested 
from control untreated tumours and tumours treated with combination free drug 
solutions and combination polymersomes on Day 7. Gene expression in treated 
groups was compared to untreated after data were normalised using a reference gene 
set (Beta actin, 18s ribosomal RNA and GAPDH). Expression changes for all genes 
are shown as scatter plots (Figure 13A). Genes were significantly different if they fell 
to the left of the vertical line and above or below the horizontal lines (student t-test). 
The combination solution scatter plot reveals an alteration in genetic profile compared 
to untreated, highlighting a significant reduction in 6 pro survival genes and a 
significant increase in 2 pro survival genes. The combination drug loaded 
polymersomes scatter plots showed a similar trend to combination free drug solution, 
9 pro survival genes were down regulated and 3 pro survival genes were upregulated. 
However, it is notable that combination drug loaded polymersomes causes the scatter 
plot genes to shift to the bottom left, therefore causing a greater significant reduction 
in pro survival genes compared to combination free drug solutions. Figure 13B shows 
specific genes that are significantly up-regulated or down-regulated in either of the 
treatment groups compared to untreated (set at 0 % expression). Combination free 
drug solution and combination drug loaded polymersomes causes a reduction in the 
majority of genes associated with apoptosis, cancer stem cells, angiogenesis, hypoxia, 
poor patient survival and autophagy compared to the untreated.    
The expression of three pro-apoptotic (BIK, BAX and CASP3) and one anti-apoptotic 
gene (BCL2) were analysed and it was unexpected that treatment with both the free 
and polymersome-based treatments led to down-regulation of both the pro-apoptotic 
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BIK and BAX genes and yet the anti-apoptotic BCL2 was also down regulated.  
Although the inter-relationship between these gene products is complex [58,59], it has 
been shown that survival of BxPC3 cells can be enhanced by upregulation of BCL2 
and down-regulation of BAX [60].  Indeed, resistance to gemcitabine in this cell line 
has been demonstrated to result from ERK1/2 mediated up-regulation of BCL2 and 
down-regulation of BAX [60].   The observation that our treatments result in down-
regulation of both of these genes may be fortuitous and the overall ratio of both may 
be resulting in a pro-apoptotic effect.   The result for significant up-regulation of CASP3 
following treatment with the polymersome formulation could confirm this suggestion 
since it is up-regulated by both intrinsic and extrinsic apoptotic signalling pathways 
and provides further evidence for the enhanced effects on tumour size/doubling time 
following treatment with the polymersome formulation.     
Hypoxia is very common in pancreatic tumours and is a contributing factor in treatment 
failure. Hypoxic stress results in the establishment of more resistant tumours cells with 
an aggressive phenotype [61-64]. Pro-oncogenic RUNX2 gene becomes upregulated 
under hypoxic stress and is partly responsible for driving tumour progression by 
targeting genes associated with apoptosis, angiogenesis and metastasis [65-68]. 
Encouragingly, our combination free drug solution and combination drug loaded 
polymersome treatment causes a reduction (-78% and -99%) in RUNX2 expression 
compared to untreated. Furthermore, an elevated anti-angiogenic effect is noted in 
combination drug loaded polymersome compared to combination free drug solution 
via a reduction of endothelial cell recruitment and survival via VEGFC and IL-8, 
therefore preventing tumour vascular support [67]. Cancer stem cells (CSC) are a 
small population of cells that are involved in tumour initiation, growth, metastasis and 
resistance to therapy [69-74]. CSC are associated with pancreatic cancer progression, 
encouragingly, 2 of the CSC associated genes investigated (NANOG and SOX2) 
showed ≥10% reduction in tumours treated with the combination drug loaded 
polymersomes when compared with expression of those genes in tumours treated with 
the combination free drug solution. Our data reveal that one out of two of the 
autophagy marker genes (CLCN7) was down-regulated in both treatment groups. 
However, CLN3 was increased by 26% in combination free drug solution treatment 
and 233% in combination drug loaded polymersomal treatment compared to the 
control [75]. Autophagy is a stress response that can enhance survival of cells that 
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have been damaged; this is clearly playing a role after our treatment, providing survival 
capability for cancer cells. This suggests that targeting autophagy could provide 
additional therapeutic benefit and enhance overall patient survival. Furthermore, the 
expression of CNDP2 and CTGF [75,76] in clinical cancer biopsies were associated 
with poor prognosis, our findings reveal CNDP2 is elevated by both treatments. 
However, CTGF is increased by 145% following treatment with the combination free 
drug solution but interestingly significantly reduced to -87% in tumours treated with the 
combination drug loaded polymersome compared to untreated therefore suggesting 
better patient outcome.  Although the above molecular genetic studies indicate positive 
attributes in terms of gene expression associated with treatment, particularly following 
treatment with the polymersome-based formulation, it may be necessary to perform 
these studies closer to the first treatment since tumours had clearly started to re-
establish at the time of harvesting.   Nevertheless, in overall terms we believe that, 
although a more in-depth study will be required to elucidate underlying molecular 
genetic mechanisms underpinning the mediation of cell death mechanism(s) elicited 
by the polymersome-based formulation, clear benefit in the current analysis appears 
to be afforded by the approach.     
 
4.0 Conclusion 
Combination cancer chemotherapy provides an important treatment tool, both as an 
adjuvant following the surgical removal of a tumour, and as a neoadjuvant therapy for 
tumours that are hard to reach and remove surgically. NP DDSs are versatile drug 
delivery systems capable of encapsulating large amounts of multiple drugs 
simultaneously, proving ideal for multi drug delivery. In addition, they offer a 
mechanism to combat multi drug resistant cancers and poor patient tolerance of the 
cytotoxic compounds utilised. Liposomes are at the forefront of NP therapy for cancer, 
however the problems associated with them provides the need for exploring other 
delivery vehicles.  In this research work, we have demonstrated the formulation of 
electroneutral polymersomes with a hydrodynamic radius of ~132nm and PDI of ~0.43 
from an amphiphilic random copolymer. The polymersomes were capable of 
simultaneously encapsulating three drugs namely 5-FU, Dox and LV within the 
aqueous core at therapeutic concentrations with an encapsulation efficiency no less 
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than 70% for any of the drugs incorporated. In addition, the release profile for the 
combined drugs was established, with each component following zero order rate 
kinetics for drug release within the first two hours. Polymersomes loaded with all three 
drugs displayed significantly better cell toxicity (36.5% cell viability) than their 
corresponding free drug solutions either independently (no drug generated a less than 
90% cell viability) or given concomitantly (75% cell viability) with good biocompatibility 
determined from the blank polymersomes. The in-vivo behaviour of the polymersome, 
in terms of biodistribution, was established and found to accumulate largely in the 
tumour tissue with up to 6-fold accumulation in the tumour after 8 hours of injection 
when compared to peripheral tissues. The polymersomes encapsulating the three 
chemotherapeutic drugs were assessed in-vivo and compared with the same 
concentration of the three drugs in solution following both intratumoral and intravenous 
administration. We can report better efficacy and higher maximum tolerated dose for 
our combination drug loaded polymersomes when compared to the combination drug 
solutions after both intratumoral and intravenous administration to mice bearing 
ectopic BxPC3 pancreatic cancer tumours. Intratumorally injected combination drug 
loaded polymersomes provided a 2% decrease in tumour volume after 13 days when 
compared with the combination solutions which yielded a 60% increase in tumour 
volume following the completion of the study. A smaller 40% increase in tumour 
volume was observed for combination drug loaded polymersomes when given 
intravenously, however this was an improvement on the 53% increase displayed by 
tumours following treatment with the combination free drug solutions at day 7. The 
combination solution demonstrated extreme cardiotoxicity and weight loss in treated 
mice whereas only very limited toxicity was observed for the combination drug loaded 
polymersome. To further support these findings, the tumours were excised, and 
genetic profiling carried out. In addition to demonstrating gene expression profiles that 
were suggestive of treatment induced apoptosis, treatment with the combination drug 
loaded polymersomes favoured down regulation of genes that would normally drive 
tumour survival, suggesting decreased angiogenesis, alleviation of hypoxia-induced 
stress and a reduction in stem cellness.    In conclusion, the results described herein 
using this novel formulation provide significant preclinical evidence to suggest that 
such formulations could play a significant clinical role in the fight against cancer. They 
achieve this by enabling the formulation of multiple drugs into a single, easily 
administered dosage form that could also preclude many of the adverse effects 
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associated with conventional combination drug-based approaches. In addition, they 
have the ability to encapsulate drugs that have both high polarities and well as those 
that are non-polar, thus ensuring that both drug solubility and cell permeability can be 
overcome from a drug delivery perspective. 
Future work for these NPs will include the optimisation of payloads to ensure that the 
full potential of these DDSs can be met and improve upon the IV results. In addition, 
the introduction of drug targeting moieties can be covalently linked to the polymer 
backbone prior to formulation [28,46] or indeed the incorporation of activating 
compounds to allow for  triggered release [77] further reducing unwanted side effects 
of these toxic therapies while reducing payload and cost. The future of simultaneous 
delivery using polymersomes is very promising. 
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Statement of significance for manuscript entitled “Electroneutral polymersomes for 
the targeted delivery of three cancer chemotherapy drugs: In-vitro and in-vivo 
evaluation”. 
 
The shift in focus from mono to combination chemotherapies has led to an increased interest in 
the role of drug delivery systems (DDS). Liposomes, although commercialized for mono therapy, 
have lower loading capacities and stability than their polymeric counterpart, polymersomes. 
Polymersomes are growing in prevalence as their advantageous properties are better understood 
and exploited. Here we present a novel polymersome for the encapsulation of three anticancer 
compounds. This is the first time this particular polymersome has been used to encapsulate these 
three compounds with both an in-vitro and in-vivo evaluation carried out. This work will be of 
  
28 
 
interest to those in the field of combination therapy, drug delivery, drug toxicity, multidrug 
resistance, liposomes, DDS and polymersomes.   
 
 
Tables 
Table 1. Characterisation and encapsulation efficiency of various polymersomal 
formulations, both with single occupancy drugs and combination occupancy.  
 
 
 Blank DOX only  5-FU only LV only Combination of 
all three 
Size (nm) 141 ± 18.2 235.6±35.5 205 ± 3.3 175 ± 38.2 133 ± 35.5 
PDI 0.27 ± 0.06  0.40±0.01 0.44 ± 0.02 0.4 ± 0.05 0.43 ± 0.14 
Zeta (mV) -0.82 mV 
±0.2 
 -
1.15±1.11 
-1.02±0.93  -1.6±0.6 -2.79 ±1.22 
Encapsulation 
efficiency (%) 
N/A 87.2±1.7 81.4±1.6 89.7±0.5 Dox     81.5 ± 5.5 
5-FU   74.5 ± 
20.1  
LV       72.1 ± 0.7 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
